We strongly oppose the approval of this modified risk application for six Camel Snus smokeless tobacco products. If Camel Snus are declared to be a MRTP, there is a risk of increased use of these products, due to perceptions of safety as well as the appeal of flavored products.
Read More »On Health Policy
Statement of Dr. Diana Zuckerman, resident of Chevy Chase, Maryland and president of the National Center for Health Research
December 23, 2020. Montgomery County should only approve the abadonment of Ellsworth Dr. if they provide a surface other than artificial turf or other artificial rubber products.
Read More »NCHR’s Public Comments on Breast Cancer Treatment for Premenopausal Women
We strongly recommend that clinical trials on breast cancer treatments should include pre-menopausal women.
Read More »Diana Zuckerman’s Public Health presentation at FDA MDUFA Meeting, October 27, 2020
MDUFA performance goals need to be more patient-centered by including specific metrics pertaining to safety and effectiveness, both pre-market and post-market, and improving patients and consumer advocates’ access to meet with FDA decision-making officials. That will help provide the safeguards that patients and consumers deserve.
Read More »Open Letter to Stephen M. Hahn, M.D., Commissioner of the Food and Drug Administration: #ProtectTheFDA
September 25, 2020 We, the undersigned experts in regulatory science and medicine, are concerned about decisionmaking at the FDA related to the COVID-19 crisis. We are writing because there have been a number of headlines recently about the adequacy of the FDA’s evidentiary standards related to COVID-19 vaccines and its authority to make science-driven assessments […]
Read More »